Trichoscopic Markers and Clinical Response Patterns With Ritlecitinib in Severe Alopecia Areata: 24-Week Outcomes From a Prospective Real-World Cohort

    January 2026 in “ Dermatologic Therapy ”
    N Perrotta, Luigi Angelo Fiorito, Roberta Vescovo, Antonio Ricupito, Giuseppe Paolo Antonio Gemma, Elisabetta Angela Campanale, Marco Virone, Riccardo Sadun, Giulio Bortone, Alfredo Rossi, Annunziata Dattola, Steven Paul Nisticò, Giovanni Pellacani, Lorenzo Ala
    TLDR Ritlecitinib is effective and safe for treating severe alopecia areata, showing significant hair regrowth and improved mental health.
    This study evaluated the effectiveness and safety of ritlecitinib in 30 adults with severe alopecia areata over 24 weeks. The mean Severity of Alopecia Tool (SALT) score decreased significantly from 79.7 to 44.5, with 43.3% of patients achieving a SALT score of ≤ 20. Trichoscopic evaluations indicated early and progressive hair regrowth, and patient-reported outcomes showed improvements in anxiety and depression scores. No serious adverse events were reported, and laboratory parameters remained stable. The study concludes that ritlecitinib is effective and safe for treating severe alopecia areata, with detailed response patterns observed through various assessment methods.
    Discuss this study in the Community →

    Research cited in this study

    14 / 14 results